標題: Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive licens [打印本頁] 作者: 瘦削 時間: 2025-3-21 17:32
書目名稱Chronic Myeloid Leukemia影響因子(影響力)
書目名稱Chronic Myeloid Leukemia影響因子(影響力)學科排名
書目名稱Chronic Myeloid Leukemia網絡公開度
書目名稱Chronic Myeloid Leukemia網絡公開度學科排名
書目名稱Chronic Myeloid Leukemia被引頻次
書目名稱Chronic Myeloid Leukemia被引頻次學科排名
書目名稱Chronic Myeloid Leukemia年度引用
書目名稱Chronic Myeloid Leukemia年度引用學科排名
書目名稱Chronic Myeloid Leukemia讀者反饋
書目名稱Chronic Myeloid Leukemia讀者反饋學科排名
作者: 敵意 時間: 2025-3-21 20:15
The Biology and Pathogenesis of Chronic Myeloid Leukaemia,he discovery of the Philadelphia (Ph) chromosome. This genomic abnormality is the result of a t(9;22) translocation, leading to the fusion oncogene, .. The resulting protein is capable of hijacking a vast repertoire of cellular functions that drive myeloid hyperplasia, characteristic of the initial,作者: 憤慨點吧 時間: 2025-3-22 01:11
Epidemiology of Chronic Myeloid Leukaemia,r epidemiological research. CML registries with a more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.3/100,000, median age at di作者: 國家明智 時間: 2025-3-22 08:27 作者: Decline 時間: 2025-3-22 09:56 作者: Discrete 時間: 2025-3-22 14:53 作者: Discrete 時間: 2025-3-22 17:38 作者: Diluge 時間: 2025-3-23 01:12
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia: 2021 Update,d to define time-related clinical milestones as well as eligibility for stopping treatment. To improve the comparability of molecular monitoring results between centers, an international scale (IS) for . measurement has been implemented by testing laboratories worldwide, either by the derivation of 作者: 凈禮 時間: 2025-3-23 03:50 作者: 阻礙 時間: 2025-3-23 06:39 作者: insidious 時間: 2025-3-23 11:24 作者: 售穴 時間: 2025-3-23 15:31 作者: Antigen 時間: 2025-3-23 18:49
The Interferon-Alpha Revival in CML,cludes immune activation and specific targeting of CML stem cells. Early studies of IFNα in CML demonstrated that it could induce extremely stable remissions, which correlated with long-term survival. Some patients even sustained their remission after discontinuing therapy, but the mechanism underly作者: 審問 時間: 2025-3-24 02:02 作者: 傻瓜 時間: 2025-3-24 04:53
Response-Related Predictors of Survival and of Treatment-Free Remission in CML,ical and cytogenetic response is still a desirable early measure of response. However measurement of the level of . transcripts in the blood by qRT-PCR, adjusted to the international scale (IS), is now the primary means of monitoring response. Achieving time-dependent molecular targets is a strong p作者: Magnitude 時間: 2025-3-24 10:10
Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Pats who respond to TKI is now considered very close to that of the healthy population control. Several clinical trials have demonstrated that some patients with CML in chronic phase who achieve sustained deep molecular remission (DMR) on TKI therapy can safely discontinue therapy and attempt treatment作者: 污穢 時間: 2025-3-24 12:47
2197-9766 nostic aspects and early response prediction.Examines the ch.This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management作者: 骯臟 時間: 2025-3-24 15:36
Book 2021Latest editionwith advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (作者: Customary 時間: 2025-3-24 19:28
https://doi.org/10.1007/978-3-663-11257-0 chronic phase of the disease. However, the mechanisms of resistance and disease progression are less well defined. In this chapter, we explore the various pathways involved in the pathogenesis of CML and also the biological events underpinning progression to the more advanced stages of the disease.作者: Minatory 時間: 2025-3-24 23:54
https://doi.org/10.1007/978-3-658-20005-3-free remission (TFR). It should be considered a future criterion for evaluating a successful clinical trial that will account for quality of life and economic factors, important aspects to consider..The question of cure of CML is now one of the major concerns and must be considered in the management of the disease.作者: Carbon-Monoxide 時間: 2025-3-25 06:51
The Biology and Pathogenesis of Chronic Myeloid Leukaemia, chronic phase of the disease. However, the mechanisms of resistance and disease progression are less well defined. In this chapter, we explore the various pathways involved in the pathogenesis of CML and also the biological events underpinning progression to the more advanced stages of the disease.作者: cushion 時間: 2025-3-25 09:08 作者: FLIRT 時間: 2025-3-25 14:37
At-Risk Practices That No Longer Workb is a highly active but more toxic third-generation TKI approved in 2012 as a last option or for patients with T315I-mutated CML patients. Internationally, many countries have added CML TKIs to their national formularies; however, despite their clinical benefits for patients, affordability of TKIs remains a significant concern in the US.作者: 喚起 時間: 2025-3-25 16:39 作者: 剝皮 時間: 2025-3-25 20:51
Reflexive Practice for the Times We Live In Panel for quantitation of . mRNA. More recent attention has focused on defining deep molecular response (DMR) within the context of the IS and pushing the limit of detection of the test. While there has been substantial progress, accurate and sensitive . measurement remains technically challenging and standardization is an ongoing process.作者: 船員 時間: 2025-3-26 02:21 作者: Notify 時間: 2025-3-26 05:33
2197-9766 ts implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.?.978-3-030-71915-9978-3-030-71913-5Series ISSN 2197-9766 Series E-ISSN 2197-9774 作者: Statins 時間: 2025-3-26 10:43
https://doi.org/10.1007/978-3-658-35078-9d they were able to improve their preparation technique and report a series of seven patients all displaying a minute chromosome. In accordance with the Committee for the Standardization of Chromosomes, Tough and colleagues called this minute chromosome Philadelphia chromosome after the city it was 作者: 巡回 時間: 2025-3-26 16:37 作者: 防止 時間: 2025-3-26 17:53 作者: 帽子 時間: 2025-3-26 22:57 作者: Adornment 時間: 2025-3-27 02:38 作者: 減去 時間: 2025-3-27 06:42
The Turbulent Environment, Then and Nowreating other causes of death as competing risks are highlighted. In the presence of competing risks, the application of both the cause-specific hazard model and the subdistribution hazard model is recommended when investigating the influence of prognostic factors on the event of interest. A detaile作者: FACET 時間: 2025-3-27 09:40
https://doi.org/10.1007/978-3-030-63875-7ee remission has become a goal of CML treatment, although, so far, it can be reached by a minority of patients. In this chapter we discuss these advances and other still open issues in CML management, analyzing some key points of the ELN 2020 recommendations.作者: 六個才偏離 時間: 2025-3-27 14:55 作者: ESO 時間: 2025-3-27 20:49 作者: 6Applepolish 時間: 2025-3-28 00:27
Die Hermeneutik der Psychopathologie,ses with imatinib therapy. Furthermore, emerging data from combination trials with second-generation TKIs suggest long-term use of IFNα may deepen molecular responses in CML patients. However, the undesirable side effects of IFNα can make this therapy difficult to deliver, and the optimal therapeuti作者: 交響樂 時間: 2025-3-28 05:32
Ein Zeitalter radikaler Ungewissheitlity in either male or female patients. However, and dependent on individual circumstances, it may be useful to discuss the options for fertility preservation including semen cryopreservation, ovarian or oocyte retrieval and storage and embryo cryopreservation. The TKI are teratogenic and should not作者: hangdog 時間: 2025-3-28 07:02
https://doi.org/10.1007/978-3-658-20005-3dvanced-phase disease. Treatment failure mandates a switch in therapy, usually to a more potent TKI, if possible. In between optimal response and treatment failure, there is a “warning category” where outcomes are generally inferior and therapeutic decisions are more complex. Recently, the importanc作者: 禮節(jié) 時間: 2025-3-28 11:02
Cytogenetics of Chronic Myeloid Leukemia (CML),d they were able to improve their preparation technique and report a series of seven patients all displaying a minute chromosome. In accordance with the Committee for the Standardization of Chromosomes, Tough and colleagues called this minute chromosome Philadelphia chromosome after the city it was 作者: 思鄉(xiāng)病 時間: 2025-3-28 15:04 作者: Formidable 時間: 2025-3-28 19:27 作者: 輕彈 時間: 2025-3-29 01:58 作者: 牛馬之尿 時間: 2025-3-29 04:07 作者: 出汗 時間: 2025-3-29 07:48
Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disereating other causes of death as competing risks are highlighted. In the presence of competing risks, the application of both the cause-specific hazard model and the subdistribution hazard model is recommended when investigating the influence of prognostic factors on the event of interest. A detaile作者: Abnormal 時間: 2025-3-29 13:34
A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloiee remission has become a goal of CML treatment, although, so far, it can be reached by a minority of patients. In this chapter we discuss these advances and other still open issues in CML management, analyzing some key points of the ELN 2020 recommendations.作者: 顯微鏡 時間: 2025-3-29 16:23 作者: Malaise 時間: 2025-3-29 20:48
CML End Phase and Blast Crisis: Implications and Management, of TKI should be directed by the mutation profile of the patient. Also, a better pathophysiologic understanding of BC is addressed. Current treatment options are combined in a concluding strategy for the management of CML end phase and BC.作者: 調味品 時間: 2025-3-30 00:19 作者: chance 時間: 2025-3-30 06:14
Managing Pregnancy in Chronic Myeloid Leukaemia,lity in either male or female patients. However, and dependent on individual circumstances, it may be useful to discuss the options for fertility preservation including semen cryopreservation, ovarian or oocyte retrieval and storage and embryo cryopreservation. The TKI are teratogenic and should not作者: beta-cells 時間: 2025-3-30 08:11
Response-Related Predictors of Survival and of Treatment-Free Remission in CML,dvanced-phase disease. Treatment failure mandates a switch in therapy, usually to a more potent TKI, if possible. In between optimal response and treatment failure, there is a “warning category” where outcomes are generally inferior and therapeutic decisions are more complex. Recently, the importanc作者: 競選運動 時間: 2025-3-30 12:38
Book 2021Latest editions of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.?.作者: 衰老 時間: 2025-3-30 18:08
https://doi.org/10.1007/978-3-030-71913-5Chronic myeloid leukaemia; BCR-ABL; Tyrosine kinase inhibitors; Philadelphia chromosome; Fertility; Hemat作者: 美學 時間: 2025-3-30 21:40 作者: 使害羞 時間: 2025-3-31 01:09 作者: Fecundity 時間: 2025-3-31 06:09 作者: Affluence 時間: 2025-3-31 09:21
https://doi.org/10.1007/978-3-663-11257-0r epidemiological research. CML registries with a more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.3/100,000, median age at di作者: Dysarthria 時間: 2025-3-31 15:56 作者: 鳥籠 時間: 2025-3-31 17:35 作者: originality 時間: 2025-4-1 00:22 作者: adequate-intake 時間: 2025-4-1 03:15
At-Risk Practices That No Longer Workh chronic myeloid leukemia (CML). There are currently five branded TKIs approved in the United States (US) and European Union (EU) for CML treatment, and one generic option (Gleevec’s generic, imatinib). Imatinib, a first-generation TKI, was the first treatment approved for CML by the European Medic作者: 寬敞 時間: 2025-4-1 06:26
Reflexive Practice for the Times We Live Ind to define time-related clinical milestones as well as eligibility for stopping treatment. To improve the comparability of molecular monitoring results between centers, an international scale (IS) for . measurement has been implemented by testing laboratories worldwide, either by the derivation of 作者: Geyser 時間: 2025-4-1 10:55 作者: 漂白 時間: 2025-4-1 18:00
https://doi.org/10.1007/978-3-030-63875-7chronic myeloid leukemia (CML), contributing to the improvement of its management. During this period several tyrosine-kinase inhibitors (TKIs) have been developed, allowing most CML patients to reach survival similar to that of the general population. Disease phase classification has partially chan
